Blog Band - Page 17 of 299

03

Sep 2025

Merck Reports Topline P-III (CORALreef Lipids) Trial Data of Enlicitide Decanoate to Treat Hypercholesterolemia

Shots: Merck has reported topline P-III (CORALreef Lipids) trial data assessing enlicitide decanoate vs PBO for the treatment of adults with hypercholesterolemia receiving mod. to high-intensity statins or are intolerant…

03

Sep 2025

NEWS

Novatim Immune Therapeutics (Keyi Pharmaceutical) Inks a ~$1.16B Licensing Deal with RADIANCE Biopharma for KY-0301 to Treat Cancer

Shots: Novatim has entered into an exclusive global licensing agreement (excl. China) with RADIANCE Biopharma for KY-0301 to treat cancer As per the deal, RADIANCE Biopharma will receive rights to…

03

Sep 2025

NEWS

Enlaza Therapeutics Collaborates with Vertex to Develop Drug Conjugates and T-Cell Engagers for Improved Conditioning and Autoimmune Diseases

Shots: Enlaza & Vertex’s muti-target collaboration will leverage Enlaza’s War-Lock platform to develop small format drug conjugates & T-cell engagers for autoimmune diseases & improved conditioning in sickle cell disease…

03

Sep 2025

NEWS

Arrowhead Enters a ~$2.2B Deal with Novartis for ARO-SNCA and TRiM-Based Therapies to Treat Neurodegenerative Diseases

Shots: Arrowhead has granted Novartis exclusive global rights to develop, manufacture, & commercialize ARO-SNCA, which leverages the TRiM platform for SC dosing & targeted gene delivery to treat synucleinopathies, incl.…

03

Sep 2025

NEWS

Henlius and Organon Receive the US FDA’s Approval for Bildyos & Bilprevda (Biosimilars, Prolia & Xgeva)

Shots: The US FDA has approved Bildyos (60mg/mL) & Bilprevda (120mg/1.7mL), biosimilar versions of Amgen’s Prolia & Xgeva (denosumab) for all indications of the reference product Approval was based on…

03

Sep 2025

EVENTS

Peptides & Complex Generics Symposium | Sep 25-26, 2025 | Mumbai, India

The Mumbai Biocluster, an initiative of the Institute of Chemical Technology (ICT), Mumbai, and operated as a Section-8 non-profit organization, proudly announces the inaugural edition of the Peptides & Complex…

02

Sep 2025

INSIGHTS+

Key Biosimilars Events of August 2025

Shots: Biosimilars are developed to be highly similar of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded…

02

Sep 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | SEP 02, 2025 | PHARMASHOTS

02

Sep 2025

NEWS

IDEAYA Biosciences Partners with Servier to Develop and Commercialize Darovasertib for Uveal Melanoma (UM)

Shots: IDEAYA has entered an exclusive licensing agreement granting Servier global regulatory and commercial rights to darovasertib, while retaining all the US rights IDEAYA & Servier will co-develop darovasertib &…

02

Sep 2025

NEWS

Polpharma Biologics Enters into Licensing Deals with MS Pharma for Multiple Biosimilar Candidates

Shots: Polpharma has entered into licensing deals with MS Pharma to commercialize PB016 (vedolizumab), PB018 (ocrelizumab), & PB019 (guselkumab) biosimilars across the Middle East & North Africa (MENA) region As…

Merck Reports Topline P-III (CORALreef Lipids) Trial Data of Enlicitide Decanoate to Treat Hypercholesterolemia

Novatim Immune Therapeutics (Keyi Pharmaceutical) Inks a ~$1.16B Licensing Deal with RADIANCE Biopharma for KY-0301 to Treat Cancer

Enlaza Therapeutics Collaborates with Vertex to Develop Drug Conjugates and T-Cell Engagers for Improved Conditioning and Autoimmune Diseases

Arrowhead Enters a ~$2.2B Deal with Novartis for ARO-SNCA and TRiM-Based Therapies to Treat Neurodegenerative Diseases

Henlius and Organon Receive the US FDA’s Approval for Bildyos & Bilprevda (Biosimilars, Prolia & Xgeva)

Peptides & Complex Generics Symposium | Sep 25-26, 2025 | Mumbai, India

Key Biosimilars Events of August 2025

LIFE SCIENCES | DAILY NEWS | SEP 02, 2025 | PHARMASHOTS

IDEAYA Biosciences Partners with Servier to Develop and Commercialize Darovasertib for Uveal Melanoma (UM)

Polpharma Biologics Enters into Licensing Deals with MS Pharma for Multiple Biosimilar Candidates

Contact US

OUR INFORMATION

FOLLOW US